TNFα blockade in human diseases: An overview of efficacy and safety

Clinical Immunology

Volumn 126, Issue 1, 2008, Pages 13-30

  Lin, Jan ^a   Ziring, David ^a   Desai, Sheetal ^a   Kim, Sungjin ^a   Wong, Maida ^a   Korin, Yael ^a   Braun, Jonathan ^a   Reed, Elaine ^a   Gjertson, David ^a   Singh, Ram Raj ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adalimumab; Ankylosing spondylitis; Autoimmune diseases; Biologic therapies; Bronchial asthma; Congestive heart failure; Crohn's disease; Cytokines; Etancerceot; Glomerulonephritis; Hepatitis; Immunotherapy; Infection; Inflammatory bowel disease; Inflammatory diseases; Infliximab; Juvenile idiopathic arthritis; Multiple sclerosis; Psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Sarcoidosis; Tuberculosis; Tumor necrosis factor alpha; Ulcerative colitis; Vasculitis

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PSORALEN; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANKYLOSING SPONDYLITIS; APLASTIC ANEMIA; ASTHMA; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; BLOOD DYSCRASIA; CONGESTIVE HEART FAILURE; CROHN DISEASE; DEMYELINATING DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; ENTERITIS; GLOMERULONEPHRITIS; GRAFT VERSUS HOST REACTION; HEPATITIS; HUMAN; IMMUNOTHERAPY; INFECTION; INFLAMMATORY DISEASE; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOMA; MULTIPLE SCLEROSIS; MYCOSIS; PANCYTOPENIA; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUVA; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SHORT SURVEY; SOLID TUMOR; TUBERCULOSIS; UVEITIS; VASCULITIS; VIRUS INFECTION; ARTHRITIS; DRUG ANTAGONISM; INFLAMMATION; METABOLISM; REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 37249063841     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2007.08.012     Document Type: Short Survey

References (125)

1. Pincus T., Callahan L., Sale W., Brooks A., Payne L., and Vaughn W. Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years. Arthritis Rheum. 27 (1984) 864-872
2. Furst D.E. Rational use of disease-modifying antirheumatic drugs. Drugs 39 (1990) 19-37
3. Williams R.O., Feldmann M., and Maini R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 9784-9788
4. Chu C., Field M., Feldmann M., and Maini R. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum. 34 (1991) 1125-1132
5. Charles P., Elliott M.J., Davis D., Potter A., Kalden J.R., Antoni C., Breedveld F.C., Smolen J.S., Eberl G., deWoody K., Feldmann M., and Maini R.N. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J. Immunol. 163 (1999) 1521-1528
6. Weinblatt M., Kremer J., Bankhurst A., Bulpitt K., Fleischmann R., Fox R., Jackson C., Lange M., and Burge D. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340 (1999) 253-259
7. Lipsky P.E., van der Heijde D.M., St Clair E.W., Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldmann M., Harriman G.R., and Maini R.N. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. 343 (2000) 1594-1602
8. Weinblatt M.E., Keystone E.C., Furst D.E., Moreland L.W., Weisman M.H., Birbara C.A., Teoh L.A., Fischkoff S.A., and Chartash E.K. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 48 (2003) 35-45
9. Keystone E.C., Kavanaugh A.F., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., Fischkoff S.A., and Chartash E.K. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 50 (2004) 1400-1411
10. Westhovens R., Yocum D., Han J., Berman A., Strusberg I., Geusens P., and Rahman M.U. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 54 (2006) 1075-1086
11. Klareskog L., van der Heijde D., de Jager J.P., Gough A., Kalden J., Malaise M., Martin Mola E., Pavelka K., Sany J., Settas L., Wajdula J., Pedersen R., Fatenejad S., and Sanda M. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363 (2004) 675-681
12. Breedveld F.C., Weisman M.H., Kavanaugh A.F., Cohen S.B., Pavelka K., van Vollenhoven R., Sharp J., Perez J.L., and Spencer-Green G.T. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54 (2006) 26-37
13. Moreland L., Schiff M., Baumgartner S., Tindall E., Fleischmann R., Bulpitt K., Weaver A., Keystone E., Furst D., Mease P., Ruderman E., Horwitz D., Arkfeld D., Garrison L., Burge D., Blosch C., Lange M., McDonnell N., and Weinblatt M. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. 130 (1999) 478-486
14. van de Putte L.B., Atkins C., Malaise M., Sany J., Russell A.S., van Riel P.L., Settas L., Bijlsma J.W., Todesco S., Dougados M., Nash P., Emery P., Walter N., Kaul M., Fischkoff S., and Kupper H. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63 (2004) 508-516
15. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., Wasko M.C., Moreland L.W., Weaver A.L., Markenson J., Cannon G.W., Spencer-Green G., and Finck B.K. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46 (2002) 1443-1450
16. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., Keystone E., Schiff M., Kalden J.R., Wang B., Dewoody K., Weiss R., and Baker D. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 50 (2004) 3432-3443
17. Smolen J.S., Van Der Heijde D.M., St Clair E.W., Emery P., Bathon J.M., Keystone E., Maini R.N., Kalden J.R., Schiff M., Baker D., Han C., Han J., and Bala M. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 54 (2006) 702-710
18. Mease P.J., Goffe B.S., Metz J., VanderStoep A., Finck B., and Burge D.J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356 (2000) 385-390
19. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., Salonen D., Rubenstein J., Sharp J.T., and Tsuji W. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 50 (2004) 2264-2272
20. Mease P.J., and Antoni C.E. Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis. 64 Suppl. 2 (2005) ii78-ii82
21. Kruithof E., Van den B.F., Baeten D., Herssens A., De K.F., Mielants H., and Veys E.M. Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann. Rheum. Dis. 61 (2002) 207-212
22. Antoni C., Krueger G.G., de V.K., Birbara C., Beutler A., Guzzo C., Zhou B., Dooley L.T., and Kavanaugh A. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann. Rheum. Dis. 64 (2005) 1150-1157
23. Mease P.J., Gladman D.D., Ritchlin C.T., Ruderman E.M., Steinfeld S.D., Choy E.H., Sharp J.T., Ory P.A., Perdok R.J., and Weinberg M.A. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52 (2005) 3279-3289
24. Gladman D.D., Mease P.J., Ritchlin C.T., Choy E.H., Sharp J.T., Ory P.A., Perdok R.J., and Sasso E.H. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 56 (2007) 476-488
25. Anandarajah A., and Ritchlin C.T. Treatment update on spondyloarthropathy. Curr. Opin. Rheumatol. 17 (2005) 247-256
26. Braun J., Brandt J., Listing J., Zink A., Alten R., Golder W., Gromnica-Ihle E., Kellner H., Krause A., Schneider M., Sorensen H., Zeidler H., Thriene W., and Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359 (2002) 1187-1193
27. Braun J., Brandt J., Listing J., Zink A., Alten R., Burmester G., Golder W., Gromnica-Ihle E., Kellner H., Schneider M., Sorensen H., Zeidler H., Reddig J., and Sieper J. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum. 48 (2003) 2224-2233
28. Braun J., Brandt J., Listing J., Zink A., Alten R., Burmester G., Gromnica-Ihle E., Kellner H., Schneider M., Sorensen H., Zeidler H., and Sieper J. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann. Rheum. Dis. 64 (2005) 229-234
29. Braun J., Baraliakos X., Brandt J., Listing J., Zink A., Alten R., Burmester G., Gromnica-Ihle E., Kellner H., Schneider M., Sorensen H., Zeidler H., and Sieper J. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 44 (2005) 670-676
30. van der H.D., Dijkmans B., Geusens P., Sieper J., DeWoody K., Williamson P., and Braun J. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 52 (2005) 582-591
31. Gorman J.D., Sack K.E., and Davis Jr. J.C. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N. Engl. J. Med. 346 (2002) 1349-1356
32. Brandt J., Khariouzov A., Listing J., Haibel H., Sorensen H., Grassnickel L., Rudwaleit M., Sieper J., and Braun J. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 48 (2003) 1667-1675
33. Davis Jr. J.C., van der H.D., Braun J., Dougados M., Cush J., Clegg D.O., Kivitz A., Fleischmann R., Inman R., and Tsuji W. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 48 (2003) 3230-3236
34. Calin A., Dijkmans B.A., Emery P., Hakala M., Kalden J., Leirisalo-Repo M., Mola E.M., Salvarani C., Sanmarti R., Sany J., Sibilia J., Sieper J., van der L.S., Veys E., Appel A.M., and Fatenejad S. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann. Rheum. Dis. 63 (2004) 1594-1600
35. van der Heijde D., Kivitz A., Schiff M.H., Sieper J., Dijkmans B.A., Braun J., Dougados M., Reveille J.D., Wong R.L., Kupper H., and Davis Jr. J.C. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 54 (2006) 2136-2146
36. Baraliakos X., Listing J., Brandt J., Zink A., Alten R., Burmester G., Gromnica-Ihle E., Kellner H., Schneider M., Sorensen H., Zeidler H., Rudwaleit M., Sieper J., and Braun J. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res. Ther. 7 (2005) R439-R444
37. Baraliakos X., Listing J., Rudwaleit M., Brandt J., Alten R., Burmester G., Gromnica-Ihle E., Haibel H., Schewe S., Schneider M., Sorensen H., Zeidler H., Visvanathan S., Sieper J., and Braun J. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J. Rheumatol. 34 (2007) 510-515
38. Braun J., Baraliakos X., Listing J., and Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum. 52 (2005) 2447-2451
39. Lovell D.J., Giannini E.H., Reiff A., Cawkwell G.D., Silverman E.D., Nocton J.J., Stein L.D., Gedalia A., Ilowite N.T., Wallace C.A., Whitmore J., and Finck B.K. Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N. Engl. J. Med. 342 (2000) 763-769
40. Lovell D.J., Giannini E.H., Reiff A., Jones O.Y., Schneider R., Olson J.C., Stein L.D., Gedalia A., Ilowite N.T., Wallace C.A., Lange M., Finck B.K., and Burge D.J. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum. 48 (2003) 218-226
41. Ten C.R., van Suijlekom-Smit L.W., Brinkman D.M., Bekkering W.P., Jansen-van Wijngaarden C.J., and Vossen J.M. Etanercept in four children with therapy-resistant systemic juvenile idiopathic arthritis. Rheumatology (Oxford) 41 (2002) 228-229
42. Quartier P., Taupin P., Bourdeaut F., Lemelle I., Pillet P., Bost M., Sibilia J., Kone-Paut I., Gandon-Laloum S., LeBideau M., Bader-Meunier B., Mouy R., Debre M., Landais P., and Prieur A.M. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 48 (2003) 1093-1101
43. Kimura Y., Pinho P., Walco G., Higgins G., Hummell D., Szer I., Henrickson M., Watcher S., and Reiff A. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. J. Rheumatol. 32 (2005) 935-942
44. Horneff G., Schmeling H., Biedermann T., Foeldvari I., Ganser G., Girschick H.J., Hospach T., Huppertz H.I., Keitzer R., Kuster R.M., Michels H., Moebius D., Rogalski B., and Thon A. The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann. Rheum. Dis. 63 (2004) 1638-1644
45. Adams A., and Lehman T.J. Update on the pathogenesis and treatment of systemic onset juvenile rheumatoid arthritis. Curr. Opin. Rheumatol. 17 (2005) 612-616
46. van Dullemen H.M., van Deventer S.J., Hommes D.W., Bijl H.A., Jansen J., Tytgat G.N., and Woody J. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109 (1995) 129-135
47. Targan S., Hanauer S., van Deventer S., Mayer L., Present D., Braakman T., DeWoody K., Schaible T., and Rutgeerts P. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337 (1997) 1029-1035
48. Lichtenstein G.R., Yan S., Bala M., Blank M., and Sands B.E. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 128 (2005) 862-869
49. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogez R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., Schaible T.F., and van Deventer S.J. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340 (1999) 1398-1405
50. Hyams J.S., Crandall W., Kugathasan S., Heuschkel R., Griffiths A., Cohen S., Markowitz J., Olsen A., Johanns J., and Baldassano R. A randomized, multicenter, open-label study to evaluate the safety and efficacy of infliximab in pediatric patients with moderate-to-severe Crohn's disease (Abstract). J. Pediatr. Gastroenterol. Nutr. 41 (2005) 539
51. Oldenburg B., and Hommes D. Biological therapies in inflammatory bowel disease: top-down or bottom-up?. Curr. Opin. Gastroenterol. 23 (2007) 395-399
52. Rispo A., Scarpa R., Di Girolamo E., Cozzolino A., Lembo G., Atteno M., De Falco T., Lo Presti M., and Castiglione F. Infliximab in the treatment of extra-intestinal manifestations of Crohn's disease. Scand. J. Rheumatol. 34 (2005) 387-391
53. Brooklyn T.N., Dunnill M.G., Shetty A., Bowden J.J., Williams J.D., Griffiths C.E., Forbes A., Greenwood R., and Probert C.S. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 55 (2006) 505-509
54. Papadakis K.A., Shaye O.A., Vasiliauskas E.A., Ippoliti A., Dubinsky M.C., Birt J., Paavola J., Lee S.K., Price J., Targan S.R., and Abreu M.T. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am. J. Gastroenterol. 100 (2005) 75-79
55. Sandborn W.J., Hanauer S.B., Lukas M., et al. Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: results of a blinded, placebo-controlled trial [abstract]. Am. J. Gastroenterol. 100 (2005) S311
56. Sandborn W.J., Hanauer S.B., Katz S., Safdi M., Wolf D.G., Baerg R.D., Tremaine W.J., Johnson T., Diehl N.N., and Zinsmeister A.R. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121 (2001) 1088-1094
57. Kyle S., Chandler D., Griffiths C.E., Helliwell P., Lewis J., McInnes I., Oliver S., Symmons D., and McHugh N. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford) 44 (2005) 390-397
58. Sandborn W.J., and Hanauer S.B. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am. J. Gastroenterol. 97 (2002) 2962-2972
59. Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C., Li S., Dooley L.T., and Griffiths C.E. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366 (2005) 1367-1374
60. Feldman S.R., Gordon K.B., Bala M., Evans R., Li S., Dooley L.T., Guzzo C., Patel K., Menter A., and Gottlieb A.B. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial. Br. J. Dermatol. 152 (2005) 954-960
61. Gordon K.B., Langley R.G., Leonardi C., Toth D., Menter M.A., Kang S., Heffernan M., Miller B., Hamlin R., Lim L., Zhong J., Hoffman R., and Okun M.M. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J. Am. Acad. Dermatol. 55 (2006) 598-606
62. Boehncke W.H., Brasie R.A., Barker J., Chimenti S., Dauden E., de Rie M., Dubertret L., Giannetti A., Katsambas A., Kragballe K., Naeyaert J.M., Ortonne J.P., Peyri J., Prinz J.C., Saurat J.H., Strohal R., van de Kerkhof P., and Sterry W. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J. Eur. Acad. Dermatol. Venereol. 20 (2006) 988-998
63. Alexis A.F., and Strober B.E. Off-label dermatologic uses of anti-TNF-a therapies. J. Cutan. Med. Surg. 9 (2005) 296-302
64. Howarth P.H., Babu K.S., Arshad H.S., Lau L., Buckley M., McConnell W., Beckett P., Al Ali M., Chauhan A., Wilson S.J., Reynolds A., Davies D.E., and Holgate S.T. Tumour necrosis factor (TNFalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60 (2005) 1012-1018
65. Cazzola M., and Polosa R. Anti-TNF-alpha and Th1 cytokine-directed therapies for the treatment of asthma. Curr. Opin. Allergy Clin. Immunol. 6 (2006) 43-50
66. Rouhani F.N., Meitin C.A., Kaler M., Miskinis-Hilligoss D., Stylianou M., and Levine S.J. Effect of tumor necrosis factor antagonism on allergen-mediated asthmatic airway inflammation. Respir. Med. 99 (2005) 1175-1182
67. Sharief M.K., and Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N. Engl. J. Med. 325 (1991) 467-472
68. Chin R.L., Sherman W.H., Sander H.W., Hays A.P., and Latov N. Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci. 210 (2003) 19-21
69. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 53 (1999) 457-465
70. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., Woody J.N., Hartung H.P., and Polman C.H. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47 (1996) 1531-1534
71. Galor A., Perez V.L., Hammel J.P., and Lowder C.Y. Differential effectiveness of Etanercept and Infliximab in the treatment of ocular inflammation. Ophthalmology 113 (2006) 2317-2323
72. Busca A., Locatelli F., Marmont F., Ceretto C., and Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. Am. J. Hematol. 82 (2007) 45-52
73. Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Burmester G.R., Emery P., Keystone E.C., Schiff M.H., van Riel P.L., Weinblatt M.E., and Weisman M.H. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann. Rheum. Dis. 65 Suppl. 3 (2006) iii2-iii15
74. Levine B., Kalman J., Mayer L., Fillit H.M., and Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323 (1990) 236-241
75. Mann D.L., McMurray J.J., Packer M., Swedberg K., Borer J.S., Colucci W.S., Djian J., Drexler H., Feldman A., Kober L., Krum H., Liu P., Nieminen M., Tavazzi L., van Veldhuisen D.J., Waldenstrom A., Warren M., Westheim A., Zannad F., and Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109 (2004) 1594-1602
76. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., and Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107 (2003) 3133-3140
77. Utz J.P., Limper A.H., Kalra S., Specks U., Scott J.P., Vuk-Pavlovic Z., and Schroeder D.R. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 124 (2003) 177-185
78. Baughman R.P., Drent M., Kavuru M., Judson M.A., Costabel U., du Bois R., Albera C., Brutsche M., Davis G., Donohue J.F., Muller-Quernheim J., Schlenker-Herceg R., Flavin S., Lo K.H., Oemar B., and Barnathan E.S. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am. J. Respir. Crit. Care Med. 174 (2006) 795-802
79. Salliot C., Gossec L., Ruyssen-Witrand A., et al. The risk of serious infections is higher in daily practice than in clinical trials for RA patients recieving TNF blockers: a systematic retrospective study of 707 patients. Arthritis Rheum. 52 (2005) 340 (Supp)
80. Kent J., Pangan A., Spencer-Green G., et al. Serious infections in patients with rheumatoid arthritis who participated in adalimumab clinical trials. Arthritis Rheum. 52 (2005) S548 (Suppl.)
81. Dixon W., Watson K., Hyrich K., et al. The incidence of serious infections is not increased in patients with rheumatoid arthritis treated with anti-TNF drugs compared to those treated with traditional DMARDs: results from anational prospective study. Arthritis Rheum. 52 (2005) S738 (Suppl.)
82. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
83. Maury E., Hochberg M., Cassell S., et al. Rheumatoid arthritis patients on TNF blockers have higher rates of infections. Arthritis Rheum. 52 (2005) S547-S548 (Suppl.)
84. Listing J., Strangfeld A., Kary S., Rau R., von Hinueber U., Stoyanova-Scholz M., Gromnica-Ihle E., Antoni C., Herzer P., Kekow J., Schneider M., and Zink A. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 52 (2005) 3403-3412
85. Wallis R.S., Kyambadde P., Johnson J.L., Horter L., Kittle R., Pohle M., Ducar C., Millard M., Mayanja-Kizza H., Whalen C., and Okwera A. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. Aids 18 (2004) 257-264
86. Bartke U., Venten I., Kreuter A., Gubbay S., Altmeyer P., and Brockmeyer N.H. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br. J. Dermatol. 150 (2004) 784-786
87. Wallis R.S., Broder M.S., Wong J.Y., Hanson M.E., and Beenhouwer D.O. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38 (2004) 1261-1265
88. Furst D., Wallis R., Broder M., and Beenhouwer D.O. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin. Arthritis Rheum. 36 (2006) 159-167
89. Wolfe F., Michaud K., Anderson J., and Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum. 50 (2004) 372-379
90. Mohan V.P., Scanga C.A., Yu K., Scott H.M., Tanaka K.E., Tsang E., Tsai M.M., Flynn J.L., and Chan J. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect. Immun. 69 (2001) 1847-1855
91. Schiff M.H., Burmester G.R., Kent J.D., Pangan A.L., Kupper H., Fitzpatrick S.B., and Donovan C. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. Ann. Rheum. Dis. 65 (2006) 889-894
92. Gomez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., and Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48 (2003) 2122-2127
93. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Coster L., Geborek P., Jacobsson L.T., Lindblad S., Lysholm J., Rantapaa-Dahlqvist S., Saxne T., Romanus V., Klareskog L., and Feltelius N. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum. 52 (2005) 1986-1992
94. Gomez-Reino J.J., Carmona L., and Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 57 (2007) 756-761
95. Carmona L., Gomez-Reino J.J., Rodriguez-Valverde V., Montero D., Pascual-Gomez E., Mola E.M., Carreno L., and Figueroa M. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. 52 (2005) 1766-1772
96. Ferrara G., Losi M., D'Amico R., Roversi P., Piro R., Meacci M., Meccugni B., Dori I.M., Andreani A., Bergamini B.M., Mussini C., Rumpianesi F., Fabbri L.M., and Richeldi L. Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study. Lancet 367 (2006) 1328-1334
97. Crum N.F., Lederman E.R., and Wallace M.R. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 84 (2005) 291-302
98. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 50 (2004) 1740-1751
99. Setoguchi S., Solomon D.H., Weinblatt M.E., Katz J.N., Avorn J., Glynn R.J., Cook E.F., Carney G., and Schneeweiss S. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum. 54 (2006) 2757-2764
100. Askling J., Fored C.M., Baecklund E., Brandt L., Backlin C., Ekbom A., Sundstrom C., Bertilsson L., Coster L., Geborek P., Jacobsson L.T., Lindblad S., Lysholm J., Rantapaa-Dahlqvist S., Saxne T., Klareskog L., and Feltelius N. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 64 (2005) 1414-1420
101. Kavanaugh A., Antoni C.E., Gladman D., Wassenberg S., Zhou B., Beutler A., Keenan G., Burmester G., Furst D.E., Weisman M.H., Kalden J.R., Smolen J., and van der Heijde D. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann. Rheum. Dis. 65 (2006) 1038-1043
102. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius N., Coster L., Geborek P., Jacobsson L.T., Lindblad S., Lysholm J., Rantapaa-Dahlqvist S., Saxne T., and Klareskog L. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann. Rheum. Dis. 64 (2005) 1421-1426
103. Stone J.H., Holbrook J.T., Marriott M.A., Tibbs A.K., Sejismundo L.P., Min Y.I., Specks U., Merkel P.A., Spiera R., Davis J.C., St Clair E.W., McCune W.J., Ytterberg S.R., Allen N.B., and Hoffman G.S. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 54 (2006) 1608-1618
104. Wolfe F., and Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. 116 (2004) 305-311
105. Sellam J., Allanore Y., Batteux F., Deslandre C.J., Weill B., and Kahan A. Autoantibody induction in patients with refractory spondyloarthropathy treated with infliximab and methotrexate. Jt. Bone Spine 72 (2005) 48-52
106. Eriksson C., Engstrand S., Sundqvist K.G., and Rantapaa-Dahlqvist S. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. Ann. Rheum. Dis. 64 (2005) 403-407
107. Klareskog L., Wajdula J., Yeh P., et al. Low autoantibody and anti-etanercept antibody formation and lack of impact on clinical outcomes after five years of treatment with etanercept in patients with rheumatoid arthritis. Arthritis Rheum. 52 (2005) S348 (supplement)
108. De Rycke L., Baeten D., Kruithof E., Van den Bosch F., Veys E.M., and De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. Arthritis Rheum. 52 (2005) 2192-2201
109. De Bandt M., Sibilia J., Le Loet X., Prouzeau S., Fautrel B., Marcelli C., Boucquillard E., Siame J.L., and Mariette X. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthritis Res. Ther. 7 (2005) R545-R551
110. Jonsdottir T., Forslid J., van Vollenhoven A., et al. Treatment with TNF alpha antagonists in patients with rheumatoid arthritis induces anti-cardiolipin antibodies. Ann. Rheum. Dis. 63 (2004) 1068-1075
111. Allanore Y., Sellam J., Batteux F., Job Deslandre C., Weill B., and Kahan A. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. Clin. Exp. Rheumatol. 22 (2004) 756-758
112. kapetanovic M., Geborek P., Saxne T., et al. Development of antibodies against infliximab treatment in rheumatoid arthritis: relation to infusion reactions and treatment response. Arthritis Rheum. 52 (2005) S543 (supplement)
113. Bartelds G., Wijbrandts C.A., Nurmohamed M.T., et al. Incidence of human anti-humanized antibodies (HAHAs) to adalimumab in relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 52 (2005) S560 (supplement)
114. Mohan N., Edwards E.T., Cupps T.R., Slifman N., Lee J.H., Siegel J.N., and Braun M.M. Leukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents. J. Rheumatol. 31 (2004) 1955-1958
115. Salmon J.E., and Alpert D. Are we coming to terms with tumor necrosis factor inhibition in pregnancy?. Arthritis Rheum. 54 (2006) 2353-2355
116. Katz J.A., Antoni C., Keenan G.F., Smith D.E., Jacobs S.J., and Lichtenstein G.R. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am. J. Gastroenterol. 99 (2004) 2385-2392
117. Hyrich K.L., Symmons D.P., Watson K.D., and Silman A.J. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum. 54 (2006) 2701-2702
118. Antoni C.E., Kavanaugh A., Kirkham B., Tutuncu Z., Burmester G.R., Schneider U., Furst D.E., Molitor J., Keystone E., Gladman D., Manger B., Wassenberg S., Weier R., Wallace D.J., Weisman M.H., Kalden J.R., and Smolen J. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 52 (2005) 1227-1236
119. Chaudhari U., Romano P., Mulcahy L.D., Dooley L.T., Baker D.G., and Gottlieb A.B. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357 (2001) 1842-1847
120. Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A., and Gottlieb A.B. Etanercept as monotherapy in patients with psoriasis. N. Engl. J. Med. 349 (2003) 2014-2022
121. Gottlieb A.B., Matheson R.T., Lowe N., Krueger G.G., Kang S., Goffe B.S., Gaspari A.A., Ling M., Weinstein G.D., Nayak A., Gordon K.B., and Zitnik R. A randomized trial of etanercept as monotherapy for psoriasis. Arch. Dermatol. 139 (2003) 1627-1632 (discussion 1632)
122. Papp K.A., Tyring S., Lahfa M., Prinz J., Griffiths C.E., Nakanishi A.M., Zitnik R., van de Kerkhof P.C., and Melvin L. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br. J. Dermatol. 152 (2005) 1304-1312
123. Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A., Lalla D., Woolley M., Jahreis A., Zitnik R., Cella D., and Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 367 (2006) 29-35
124. Menter A., Feldman S.R., Weinstein G.D., Papp K., Evans R., Guzzo C., Li S., Dooley L.T., Arnold C., and Gottlieb A.B. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J. Am. Acad. Dermatol. 56 31 (2007) e1-e15
125. Shikiar R., Heffernan M., Langley R.G., Willian M.K., Okun M.M., and Revicki D.A. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. J. Derm. Treat. 18 (2007) 25-31